TickerFacts.

Schrodinger, Inc. (SDGR): Revenue

Annual figures by period end, from SEC filings.

$255.87M
Year ended 2025-12-31
$259.04M
Trailing 12 months to 2026-06-30
+12.2%
3-year compound annual growth
+18.8%
5-year compound annual growth
2019-12-31: $85.54M2020-12-31: $108.09M2021-12-31: $137.93M2022-12-31: $180.96M2023-12-31: $216.67M2024-12-31: $207.54M2025-12-31: $255.87M$255.87M
2019-12-31 Revenue (USD) 2025-12-31
Period endedRevenueChange YoYSource filing
2025-12-31$255.87M+23.3%2026-02-25, From 2025-01-01
2024-12-31$207.54M-4.2%2026-02-25, From 2024-01-01
2023-12-31$216.67M+19.7%2026-02-25, From 2023-01-01
2022-12-31$180.96M+31.2%2025-02-26, From 2022-01-01
2021-12-31$137.93M+27.6%2024-02-28, From 2021-01-01
2020-12-31$108.09M+26.4%2022-02-24, From 2020-01-01
2019-12-31$85.54Mn/a2022-02-24, From 2019-01-01

Revenue at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedRevenueChange YoY
Schrodinger, Inc. (SDGR)2025-12-31$255.87M+23.3%
Arvinas, Inc. (ARVN)2025-12-31$262.60M-0.3%
Arcus Biosciences, Inc. (RCUS)2025-12-31$247.00M-4.3%
Ligand Pharmaceuticals Inc (LGND)2025-12-31$268.09M+60.4%
Keros Therapeutics, Inc. (KROS)2025-12-31$244.06Mn/m
Vireo Growth Inc. (VREOF)2025-12-31$268.77M+170.4%
Harrow, Inc. (HROW)2025-12-31$272.30M+36.4%
Akebia Therapeutics, Inc. (AKBA)2025-12-31$236.20M+47.5%
Anaptysbio, Inc (ANAB)2025-12-31$234.60M+157.0%

Compare SDGR, ARVN, RCUS, LGND side by side · Screen every company in Pharmaceutical Preparations ↗